Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

The US Food and Drug Administration (FDA) has approved brexpiprazole (Otsuka Pharmaceutical’s Rexulti) for the treatment of adults with schizophrenia. In the image, Building 66 of the FDA

The US Food and Drug Administration has approved brexpiprazole for use in schizophrenia and depression but warns that it should not be used to manage behavioural problems in older people with dementia-related psychosis

Source  Wikimedia Commons